ID   DAPK3_HUMAN             Reviewed;         454 AA.
AC   O43293; A0AVN4; B3KQE2; Q05JY4;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   12-OCT-2022, entry version 202.
DE   RecName: Full=Death-associated protein kinase 3;
DE            Short=DAP kinase 3;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835};
DE   AltName: Full=DAP-like kinase;
DE            Short=Dlk;
DE   AltName: Full=MYPT1 kinase;
DE   AltName: Full=Zipper-interacting protein kinase;
DE            Short=ZIP-kinase;
GN   Name=DAPK3; Synonyms=ZIPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9488481; DOI=10.1128/mcb.18.3.1642;
RA   Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.;
RT   "ZIP kinase, a novel serine/threonine kinase which mediates apoptosis.";
RL   Mol. Cell. Biol. 18:1642-1651(1998).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10356987; DOI=10.1016/s0014-5793(99)00550-5;
RA   Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.;
RT   "ZIP kinase identified as a novel myosin regulatory light chain kinase in
RT   HeLa cells.";
RL   FEBS Lett. 451:81-84(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE SPLICING,
RP   FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B, CATALYTIC
RP   ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, INTERACTION
RP   WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Urinary bladder;
RX   PubMed=17126281; DOI=10.1016/j.abb.2006.09.026;
RA   Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.;
RT   "Novel ZIP kinase isoform lacks leucine zipper.";
RL   Arch. Biochem. Biophys. 456:194-203(2006).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY.
RX   PubMed=11384979; DOI=10.1074/jbc.m102753200;
RA   Niiro N., Ikebe M.;
RT   "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle
RT   contraction via myosin light chain phosphorylation.";
RL   J. Biol. Chem. 276:29567-29574(2001).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC ACTIVITY.
RX   PubMed=11781833; DOI=10.1038/sj.onc.1205055;
RA   Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.;
RT   "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light
RT   chain and reorganization of actin filaments in nonmuscle cells.";
RL   Oncogene 20:8175-8183(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR.
RX   PubMed=12917339; DOI=10.1128/mcb.23.17.6174-6186.2003;
RA   Kawai T., Akira S., Reed J.C.;
RT   "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.";
RL   Mol. Cell. Biol. 23:6174-6186(2003).
RN   [9]
RP   INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY.
RX   PubMed=15292222; DOI=10.1074/jbc.m403676200;
RA   Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.;
RT   "Identification and characterization of zipper-interacting protein kinase
RT   as the unique vascular smooth muscle myosin phosphatase-associated
RT   kinase.";
RL   J. Biol. Chem. 279:42055-42061(2004).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY.
RX   PubMed=15096528; DOI=10.1083/jcb.200309056;
RA   Komatsu S., Ikebe M.;
RT   "ZIP kinase is responsible for the phosphorylation of myosin II and
RT   necessary for cell motility in mammalian fibroblasts.";
RL   J. Cell Biol. 165:243-254(2004).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312; SER-318
RP   AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR LOCATION.
RX   PubMed=15367680; DOI=10.1128/mcb.24.19.8611-8626.2004;
RA   Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G.,
RA   Kimchi A.;
RT   "Death-associated protein kinase phosphorylates ZIP kinase, forming a
RT   unique kinase hierarchy to activate its cell death functions.";
RL   Mol. Cell. Biol. 24:8611-8626(2004).
RN   [12]
RP   INTERACTION WITH STAT3.
RX   PubMed=16219639; DOI=10.1093/intimm/dxh331;
RA   Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y.,
RA   Ishida M., Akira S., Matsuda T.;
RT   "Physical and functional interactions between STAT3 and ZIP kinase.";
RL   Int. Immunol. 17:1543-1552(2005).
RN   [13]
RP   INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION.
RX   PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x;
RA   Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.;
RT   "TCP10L is expressed specifically in spermatogenic cells and binds to death
RT   associated protein kinase-3.";
RL   Int. J. Androl. 28:163-170(2005).
RN   [14]
RP   PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND SER-311,
RP   ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-299;
RP   299-THR-THR-300; VAL-427; VAL-434 AND LEU-441.
RX   PubMed=15611134; DOI=10.1074/jbc.m412538200;
RA   Graves P.R., Winkfield K.M., Haystead T.A.;
RT   "Regulation of zipper-interacting protein kinase activity in vitro and in
RT   vivo by multisite phosphorylation.";
RL   J. Biol. Chem. 280:9363-9374(2005).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [16]
RP   FUNCTION, ACTIVITY REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT
RP   THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161; THR-225;
RP   THR-265 AND THR-299.
RX   PubMed=17158456; DOI=10.1074/jbc.m609990200;
RA   Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H.,
RA   Loiselle D., Hosoya H., Haystead T.A.;
RT   "ROCK1 phosphorylates and activates zipper-interacting protein kinase.";
RL   J. Biol. Chem. 282:4884-4893(2007).
RN   [17]
RP   SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW.
RX   PubMed=17953487; DOI=10.1371/journal.pgen.0030180;
RA   Shoval Y., Pietrokovski S., Kimchi A.;
RT   "ZIPK: a unique case of murine-specific divergence of a conserved
RT   vertebrate gene.";
RL   PLoS Genet. 3:1884-1893(2007).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   DOI=10.1002/sita.200600112;
RA   Scheidtmann K.H.;
RT   "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple
RT   functions.";
RL   Signal Transduct. 7:248-259(2007).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF RPL13A, AND CATALYTIC ACTIVITY.
RX   PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019;
RA   Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.;
RT   "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating
RT   inflammatory gene expression.";
RL   Mol. Cell 32:371-382(2008).
RN   [20]
RP   FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION.
RX   PubMed=18084323; DOI=10.1038/sj.onc.1210995;
RA   Leister P., Felten A., Chasan A.I., Scheidtmann K.H.;
RT   "ZIP kinase plays a crucial role in androgen receptor-mediated
RT   transcription.";
RL   Oncogene 27:3292-3300(2008).
RN   [21]
RP   FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112; ASN-161
RP   AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION.
RX   PubMed=21487036; DOI=10.1158/0008-5472.can-10-3543;
RA   Brognard J., Zhang Y.W., Puto L.A., Hunter T.;
RT   "Cancer-associated loss-of-function mutations implicate DAPK3 as a tumor-
RT   suppressing kinase.";
RL   Cancer Res. 71:3152-3161(2011).
RN   [22]
RP   PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   294-ARG-ARG-295.
RX   PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016;
RA   Weitzel D.H., Chambers J., Haystead T.A.;
RT   "Phosphorylation-dependent control of ZIPK nuclear import is species
RT   specific.";
RL   Cell. Signal. 23:297-303(2011).
RN   [23]
RP   FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1.
RX   PubMed=21169990; DOI=10.1038/emboj.2010.338;
RA   Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.;
RT   "Atg1-mediated myosin II activation regulates autophagosome formation
RT   during starvation-induced autophagy.";
RL   EMBO J. 30:636-651(2011).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH NLK.
RX   PubMed=21454679; DOI=10.1074/jbc.m110.189829;
RA   Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R.,
RA   Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.;
RT   "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta-
RT   catenin signaling through interaction with Nemo-like kinase and T-cell
RT   factor 4 (NLK/TCF4).";
RL   J. Biol. Chem. 286:19170-19177(2011).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH ATF4.
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [26]
RP   FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH
RP   RHOD.
RX   PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046;
RA   Nehru V., Almeida F.N., Aspenstrom P.;
RT   "Interaction of RhoD and ZIP kinase modulates actin filament assembly and
RT   focal adhesion dynamics.";
RL   Biochem. Biophys. Res. Commun. 433:163-169(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277.
RA   Kursula P., Vahokoski J., Wilmanns M.;
RT   "Crystal structure of human ZIP kinase.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [29] {ECO:0007744|PDB:2J90}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH PYRIDONE-6,
RP   ACTIVITY REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50 AND THR-265.
RX   PubMed=18239682; DOI=10.1038/emboj.2008.8;
RA   Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W., Parker S.A.,
RA   Turk B.E., Pearl L.H., Knapp S.;
RT   "Activation segment dimerization: a mechanism for kinase
RT   autophosphorylation of non-consensus sites.";
RL   EMBO J. 27:704-714(2008).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which is involved in the regulation
CC       of apoptosis, autophagy, transcription, translation and actin
CC       cytoskeleton reorganization. Involved in the regulation of smooth
CC       muscle contraction. Regulates both type I (caspase-dependent) apoptotic
CC       and type II (caspase-independent) autophagic cell deaths signal,
CC       depending on the cellular setting. Involved in regulation of
CC       starvation-induced autophagy. Regulates myosin phosphorylation in both
CC       smooth muscle and non-muscle cells. In smooth muscle, regulates myosin
CC       either directly by phosphorylating MYL12B and MYL9 or through
CC       inhibition of smooth muscle myosin phosphatase (SMPP1M) via
CC       phosphorylation of PPP1R12A; the inhibition of SMPP1M functions to
CC       enhance muscle responsiveness to Ca(2+) and promote a contractile
CC       state. Phosphorylates MYL12B in non-muscle cells leading to
CC       reorganization of actin cytoskeleton. Isoform 2 can phosphorylate
CC       myosin, PPP1R12A and MYL12B. Overexpression leads to condensation of
CC       actin stress fibers into thick bundles. Involved in actin filament
CC       focal adhesion dynamics. The function in both reorganization of actin
CC       cytoskeleton and focal adhesion dissolution is modulated by RhoD.
CC       Positively regulates canonical Wnt/beta-catenin signaling through
CC       interaction with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon
CC       interferon-gamma activation which is causing RPL13A release from the
CC       ribosome, RPL13A association with the GAIT complex and its subsequent
CC       involvement in transcript-selective translation inhibition. Enhances
CC       transcription from AR-responsive promoters in a hormone- and kinase-
CC       dependent manner. Involved in regulation of cell cycle progression and
CC       cell proliferation. May be a tumor suppressor.
CC       {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979,
CC       ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:12917339,
CC       ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18084323,
CC       ECO:0000269|PubMed:18995835, ECO:0000269|PubMed:21169990,
CC       ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679,
CC       ECO:0000269|PubMed:21487036, ECO:0000269|PubMed:23454120}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979,
CC         ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528,
CC         ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10356987,
CC         ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833,
CC         ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281,
CC         ECO:0000269|PubMed:18995835};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10356987};
CC   -!- ACTIVITY REGULATION: A sequential activation is proposed:
CC       autophosphorylation at consensus sites is leading to dimerization of
CC       the catalytic domain stabilized by phosphorylation at Ser-50 and
CC       activation segment exchange (producing an active confirmation of both
CC       kinase modules in trans) followed by phosphorylation at Thr-180 in the
CC       activation segment and at other regulatory sites (Probable).
CC       Phosphorylation at Thr-180, Thr-225 and Thr-265 is essential for
CC       activity. Oligomerization is required for full enzymatic activity.
CC       Inhibited by pyridone-6 (K00225), a potent, ATP-competitive inhibitor.
CC       {ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456,
CC       ECO:0000269|PubMed:18239682, ECO:0000303|PubMed:18239682}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281};
CC         KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281};
CC         KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281};
CC         KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281};
CC         Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1)
CC         {ECO:0000269|PubMed:17126281};
CC   -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and
CC       homodimers are reported); monomeric in its kinase-inactive form.
CC       Homodimerization is required for activation segment autophosphorylation
CC       (Probable). Isoform 1 and isoform 2 interact with myosin and PPP1R12A;
CC       interaction of isoform 1 with PPP1R12A is inhibited by RhoA dominant
CC       negative form. Interacts with NLK, DAXX, STAT3, RHOD (GTP-bound form)
CC       and TCP10L. Interacts with PAWR; the interaction is reported
CC       conflictingly: according to PubMed:17953487 does not interact with
CC       PAWR. Interacts with ULK1; may be a substrate of ULK1.
CC       {ECO:0000269|PubMed:12917339, ECO:0000269|PubMed:15292222,
CC       ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:16219639,
CC       ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18239682,
CC       ECO:0000269|PubMed:21169990, ECO:0000269|PubMed:21408167,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:23454120,
CC       ECO:0000303|PubMed:18239682}.
CC   -!- INTERACTION:
CC       O43293; O43293: DAPK3; NbExp=3; IntAct=EBI-77293, EBI-77293;
CC       O43293; Q9UBE8: NLK; NbExp=3; IntAct=EBI-77293, EBI-366978;
CC       O43293; O14974: PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726;
CC       O43293; Q8TDR4: TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210;
CC       O43293-2; Q10728: Ppp1r12a; Xeno; NbExp=2; IntAct=EBI-9691390, EBI-918263;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}. Cytoplasm
CC       {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134,
CC       ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}.
CC       Note=Predominantly localizes to the cytoplasm but can shuttle between
CC       the nucleus and cytoplasm; cytoplasmic localization is promoted by
CC       phosphorylation at Thr-299 and involves Rho/Rock signaling.
CC       {ECO:0000269|PubMed:17953487, ECO:0000269|PubMed:20854903}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus
CC       {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus
CC       {ECO:0000269|PubMed:17126281}. Cytoplasm {ECO:0000269|PubMed:17126281}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=ZIPK-L;
CC         IsoId=O43293-1; Sequence=Displayed;
CC       Name=2; Synonyms=ZIPK-S;
CC         IsoId=O43293-2; Sequence=VSP_042059, VSP_042060;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are
CC       expressed in the bladder smooth muscle. {ECO:0000269|PubMed:15292222,
CC       ECO:0000269|PubMed:17126281}.
CC   -!- PTM: The phosphorylation status is critical for kinase activity,
CC       oligomerization and intracellular localization. Phosphorylation at Thr-
CC       180, Thr-225 and Thr-265 is essential for activity. The phosphorylated
CC       form is localized in the cytoplasm promoted by phosphorylation at Thr-
CC       299; nuclear translocation or retention is maximal when it is not
CC       phosphorylated. Phosphorylation increases the trimeric form, and its
CC       dephosphorylation favors a kinase-inactive monomeric form. Both isoform
CC       1 and isoform 2 can undergo autophosphorylation.
CC       {ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:15611134,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:20854903}.
CC   -!- MISCELLANEOUS: [Isoform 2]: The internal splice site between exon 8 and
CC       the 3' UTR, which yields this truncated isoform, is non-canonical.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. DAP kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB007144; BAA24955.1; -; mRNA.
DR   EMBL; AB022341; BAA81746.1; -; mRNA.
DR   EMBL; AK074799; BAG52004.1; -; mRNA.
DR   EMBL; BC126430; AAI26431.1; -; mRNA.
DR   EMBL; BC126432; AAI26433.1; -; mRNA.
DR   EMBL; AB265224; BAF34614.1; -; mRNA.
DR   CCDS; CCDS12116.1; -. [O43293-1]
DR   RefSeq; NP_001339.1; NM_001348.2. [O43293-1]
DR   RefSeq; XP_005259565.1; XM_005259508.1.
DR   PDB; 1YRP; X-ray; 3.10 A; A/B=1-277.
DR   PDB; 2J90; X-ray; 2.00 A; A/B=9-289.
DR   PDB; 3BHY; X-ray; 1.24 A; A=9-289.
DR   PDB; 3BQR; X-ray; 1.75 A; A=9-289.
DR   PDB; 5A6N; X-ray; 1.70 A; A/B=9-289.
DR   PDB; 5A6O; X-ray; 1.60 A; A/B=9-289.
DR   PDB; 5VJA; X-ray; 2.46 A; A/B/C/D=9-289.
DR   PDBsum; 1YRP; -.
DR   PDBsum; 2J90; -.
DR   PDBsum; 3BHY; -.
DR   PDBsum; 3BQR; -.
DR   PDBsum; 5A6N; -.
DR   PDBsum; 5A6O; -.
DR   PDBsum; 5VJA; -.
DR   AlphaFoldDB; O43293; -.
DR   SMR; O43293; -.
DR   BioGRID; 107983; 81.
DR   IntAct; O43293; 62.
DR   MINT; O43293; -.
DR   STRING; 9606.ENSP00000442973; -.
DR   BindingDB; O43293; -.
DR   ChEMBL; CHEMBL2468; -.
DR   DrugBank; DB07242; (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile.
DR   DrugBank; DB04716; 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one.
DR   DrugBank; DB07125; 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O43293; -.
DR   GuidetoPHARMACOLOGY; 2004; -.
DR   iPTMnet; O43293; -.
DR   PhosphoSitePlus; O43293; -.
DR   BioMuta; DAPK3; -.
DR   EPD; O43293; -.
DR   jPOST; O43293; -.
DR   MassIVE; O43293; -.
DR   MaxQB; O43293; -.
DR   PaxDb; O43293; -.
DR   PeptideAtlas; O43293; -.
DR   PRIDE; O43293; -.
DR   ProteomicsDB; 48863; -. [O43293-1]
DR   ProteomicsDB; 48864; -. [O43293-2]
DR   Antibodypedia; 11137; 419 antibodies from 42 providers.
DR   DNASU; 1613; -.
DR   Ensembl; ENST00000301264.7; ENSP00000301264.3; ENSG00000167657.14. [O43293-1]
DR   Ensembl; ENST00000545797.7; ENSP00000442973.1; ENSG00000167657.14. [O43293-1]
DR   GeneID; 1613; -.
DR   KEGG; hsa:1613; -.
DR   MANE-Select; ENST00000545797.7; ENSP00000442973.1; NM_001348.3; NP_001339.1.
DR   UCSC; uc002lzc.2; human. [O43293-1]
DR   CTD; 1613; -.
DR   DisGeNET; 1613; -.
DR   GeneCards; DAPK3; -.
DR   HGNC; HGNC:2676; DAPK3.
DR   HPA; ENSG00000167657; Low tissue specificity.
DR   MIM; 603289; gene.
DR   neXtProt; NX_O43293; -.
DR   OpenTargets; ENSG00000167657; -.
DR   PharmGKB; PA27144; -.
DR   VEuPathDB; HostDB:ENSG00000167657; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   GeneTree; ENSGT00940000161753; -.
DR   HOGENOM; CLU_000288_63_55_1; -.
DR   InParanoid; O43293; -.
DR   OMA; CRQKSNG; -.
DR   PhylomeDB; O43293; -.
DR   TreeFam; TF314166; -.
DR   PathwayCommons; O43293; -.
DR   Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand.
DR   SABIO-RK; O43293; -.
DR   SignaLink; O43293; -.
DR   SIGNOR; O43293; -.
DR   BioGRID-ORCS; 1613; 20 hits in 1112 CRISPR screens.
DR   ChiTaRS; DAPK3; human.
DR   EvolutionaryTrace; O43293; -.
DR   GeneWiki; DAPK3; -.
DR   GenomeRNAi; 1613; -.
DR   Pharos; O43293; Tchem.
DR   PRO; PR:O43293; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O43293; protein.
DR   Bgee; ENSG00000167657; Expressed in apex of heart and 186 other tissues.
DR   ExpressionAtlas; O43293; baseline and differential.
DR   Genevisible; O43293; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB.
DR   GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB.
DR   CDD; cd14105; STKc_DAPK; 1.
DR   InterPro; IPR042870; DAPK3_STKc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding;
KW   Chromatin regulator; Cytoplasm; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase;
KW   Translation regulation; Tumor suppressor.
FT   CHAIN           1..454
FT                   /note="Death-associated protein kinase 3"
FT                   /id="PRO_0000085914"
FT   DOMAIN          13..275
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          161..204
FT                   /note="Activation segment"
FT                   /evidence="ECO:0000250|UniProtKB:O96017"
FT   REGION          427..441
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000303|PubMed:9488481"
FT   ACT_SITE        139
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         94
FT                   /ligand="pyridone 6"
FT                   /ligand_id="ChEBI:CHEBI:87103"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:18239682,
FT                   ECO:0007744|PDB:2J90"
FT   BINDING         96
FT                   /ligand="pyridone 6"
FT                   /ligand_id="ChEBI:CHEBI:87103"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:18239682,
FT                   ECO:0007744|PDB:2J90"
FT   MOD_RES         50
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18239682"
FT   MOD_RES         180
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15611134,
FT                   ECO:0000269|PubMed:17158456"
FT   MOD_RES         225
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MOD_RES         265
FT                   /note="Phosphothreonine; by autocatalysis and ROCK1"
FT                   /evidence="ECO:0000269|PubMed:15611134,
FT                   ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682"
FT   MOD_RES         299
FT                   /note="Phosphothreonine; by autocatalysis, DAPK1 and ROCK1"
FT                   /evidence="ECO:0000269|PubMed:15367680,
FT                   ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456,
FT                   ECO:0000269|PubMed:20854903"
FT   MOD_RES         306
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MOD_RES         309
FT                   /note="Phosphoserine; by DAPK1"
FT                   /evidence="ECO:0000269|PubMed:15367680"
FT   MOD_RES         311
FT                   /note="Phosphoserine; by autocatalysis and DAPK1"
FT                   /evidence="ECO:0000269|PubMed:15367680,
FT                   ECO:0000269|PubMed:15611134"
FT   MOD_RES         312
FT                   /note="Phosphoserine; by DAPK1"
FT                   /evidence="ECO:0000269|PubMed:15367680,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         318
FT                   /note="Phosphoserine; by DAPK1"
FT                   /evidence="ECO:0000269|PubMed:15367680"
FT   MOD_RES         326
FT                   /note="Phosphoserine; by DAPK1"
FT                   /evidence="ECO:0000269|PubMed:15367680"
FT   VAR_SEQ         313..322
FT                   /note="LPPNNSYADF -> ASPIVAPVDA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17126281"
FT                   /id="VSP_042059"
FT   VAR_SEQ         323..454
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17126281"
FT                   /id="VSP_042060"
FT   VARIANT         112
FT                   /note="T -> M (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; greatly reduces kinase activity,
FT                   increases cell proliferation and cell survival)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21487036"
FT                   /id="VAR_040438"
FT   VARIANT         161
FT                   /note="D -> N (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; greatly reduces kinase activity,
FT                   increases cell proliferation and cell survival)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21487036"
FT                   /id="VAR_040439"
FT   VARIANT         216
FT                   /note="P -> S (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; greatly reduces kinase activity,
FT                   increases cell proliferation, cell adhesion and cell
FT                   survival)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21487036"
FT                   /id="VAR_040440"
FT   MUTAGEN         42
FT                   /note="K->A: Loss of kinase activity at low concentrations
FT                   of ATP."
FT                   /evidence="ECO:0000269|PubMed:17158456"
FT   MUTAGEN         161
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17158456"
FT   MUTAGEN         180
FT                   /note="T->A: Greatly reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:21487036"
FT   MUTAGEN         225
FT                   /note="T->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17158456"
FT   MUTAGEN         265
FT                   /note="T->A: Loss of phosphorylation by ROCK1,
FT                   catalytically inactive."
FT                   /evidence="ECO:0000269|PubMed:17158456"
FT   MUTAGEN         294..295
FT                   /note="RR->AA: Cytoplasmic localization."
FT                   /evidence="ECO:0000269|PubMed:20854903"
FT   MUTAGEN         299..300
FT                   /note="TT->AA: Predominantly nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MUTAGEN         299
FT                   /note="T->A: Loss of phosphorylation by ROCK1."
FT                   /evidence="ECO:0000269|PubMed:17158456"
FT   MUTAGEN         299
FT                   /note="T->D: Predominantly cytoplasmic localization;
FT                   phosphomimetic."
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MUTAGEN         427
FT                   /note="V->A: Predominantly nuclear localization; when
FT                   associated with A-434 and A-441."
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MUTAGEN         434
FT                   /note="V->A: Predominantly nuclear localization; when
FT                   associated with A-427 and A-441."
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   MUTAGEN         441
FT                   /note="L->A: Predominantly nuclear localization; when
FT                   associated with A-427 and A-434."
FT                   /evidence="ECO:0000269|PubMed:15611134"
FT   HELIX           9..12
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          13..21
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          23..32
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   TURN            33..35
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          38..46
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           49..51
FT                   /evidence="ECO:0007829|PDB:2J90"
FT   STRAND          53..56
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           58..70
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          79..84
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          86..94
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           101..108
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           113..132
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           142..144
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          145..148
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          150..154
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           171..175
FT                   /evidence="ECO:0007829|PDB:5A6N"
FT   HELIX           176..178
FT                   /evidence="ECO:0007829|PDB:5A6O"
FT   HELIX           181..183
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           186..189
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           197..212
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           222..230
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           238..241
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           246..253
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           266..271
FT                   /evidence="ECO:0007829|PDB:3BHY"
FT   HELIX           273..280
FT                   /evidence="ECO:0007829|PDB:3BHY"
SQ   SEQUENCE   454 AA;  52536 MW;  56773008A6A61CF0 CRC64;
     MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE
     IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL
     KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT
     PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY
     FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT
     RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY
     EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY
     EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR
//
